Lakefront Biotherapeutics (GLPGF) Divestments (2021 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Divestments for 4 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Divestments fell 91.83% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was -$11.0 million, a 143.72% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, up 326.65% from the prior year.
• Divestments was $2.7 million for Q1 2026 at Lakefront Biotherapeutics, up from $1.9 million in the prior quarter.
• Over five years, Divestments peaked at $33.6 million in Q1 2025 and troughed at -$25.1 million in Q2 2025.
• A 3-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Divestments.
• The widest YoY moves for Divestments: up 2408.57% in 2025, down 502.76% in 2025.
• Over 3 years, Divestments stood at $1.3 million in 2024, then soared by 40.23% to $1.9 million in 2025, then soared by 45.28% to $2.7 million in 2026.
• The last three Divestments figures came in at $2.7 million (Q1 2026), $1.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.